Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.5K | — | — | — | $10.2M | $1.16M | $75.0K | $10.0K | — | $10.8M |
| Revenue growth | — | — | — | — | — | -88.6% | -93.5% | -86.7% | — | — |
| Operating income | -$31.9M | -$33.9M | -$51.5M | -$61.4M | -$51.5M | -$63.4M | -$47.4M | -$39.3M | -$40.0M | -$153M |
| Operating margin | -172505.3% | — | — | — | -506.8% | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
| Net income | -$31.8M | -$33.3M | -$48.3M | -$57.9M | -$51.0M | -$63.4M | -$46.7M | -$36.9M | -$37.9M | -$154M |
| Net margin | -171945.1% | — | — | — | -502.1% | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
| EPS (diluted) | -$1.50 | -$1.13 | -$1.18 | -$1.34 | -$1.12 | -$1.23 | -$0.89 | -$0.58 | -$0.59 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.7M | -$29.8M | -$43.3M | -$52.0M | -$39.2M | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$71.5M |
| Capital expenditures | $704K | $294K | $126K | $145K | $68.5K | $14.9K | $84.2K | $21.4K | $9.97K | $919K |
| Free cash flow | -$30.4M | -$30.1M | -$43.5M | -$52.1M | -$39.3M | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$72.5M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $40.0M | $124M | $210M | $158M | $137M | $90.3M | $47.9M | $41.8M | $34.8M | $213M |
| Total assets | $42.4M | $129M | $215M | $168M | $143M | $94.3M | $51.8M | $45.3M | $35.6M | $240M |
| Total liabilities | $7.09M | $8.88M | $9.37M | $13.8M | $14.6M | $12.7M | $8.88M | $6.90M | $47.1M | $37.3M |
| Shareholders' equity | $35.3M | $120M | $205M | $154M | $128M | $81.6M | $42.9M | $38.4M | $0.00 | $203M |
| Retained earnings | -$119M | -$152M | -$201M | -$258M | -$309M | -$373M | -$420M | -$456M | -$17.9M | -$172M |
| Shares (wtd avg diluted) | 23.3M | 34.4M | 43.2M | 43.5M | 49.0M | 52.3M | 54.4M | 64.4M | 1.02M | 27.6M |
Every figure is extracted from CRESCENT BIOPHARMA, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.